VA
ORIC icon

VR Adviser’s Oric Pharmaceuticals ORIC Stock Holding History

VR Adviser’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.7M Sell
4,319,765
-1,356,465
-24% -$15.4M 2.04% 13
2025
Q4 		$46.4M Sell
5,676,230
-920,655
-14% -$10.6M 2.29% 14
2025
Q3 		$79.2M Hold
6,596,885
– – 4.46% 8
2025
Q2 		$67M Buy
6,596,885
+3,414,358
+107% +$22.9M 5.02% 6
2025
Q1 		$17.8M Sell
3,182,527
-1,212,000
-28% -$10.6M 1.51% 17
2024
Q4 		$35.5M Hold
4,394,527
– – 2.43% 15
2024
Q3 		$45M Hold
4,394,527
– – 2.36% 15
2024
Q2 		$31.1M Hold
4,394,527
– – 1.98% 17
2024
Q1 		$60.4M Buy
4,394,527
+1,966,142
+81% +$23.4M 2.87% 13
2023
Q4 		$22.3M Buy
2,428,385
+285,529
+13% +$2.06M 1.53% 22
2023
Q3 		$13M Hold
2,142,856
– – 1.36% 23
2023
Q2 		$16.6M Buy
+2,142,856
New +$12.2M 2.66% 16

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser's ORIC Position: Q1 2026 in Review

VR Adviser reduced its Oric Pharmaceuticals (ORIC) stake by 24% in Q1 2026, selling an estimated $15.4M and leaving 4,319,765 shares worth $54.7M. The position accounts for 2.04% of the portfolio, ranked #13.

VR Adviser first reported a position in ORIC in Q2 2023 and has held it in 12 quarters since. The position peaked at $79.2M in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • VR Adviser held 4,319,765 shares of Oric Pharmaceuticals worth $54.7M as of Q1 2026.
  • VR Adviser sold 1,356,465 Oric Pharmaceuticals shares in Q1 2026, an estimated $15.4M.
  • Oric Pharmaceuticals made up 2.04% of VR Adviser's portfolio in Q1 2026, its #13 holding.
  • VR Adviser first reported a position in Oric Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • VR Adviser's Oric Pharmaceuticals position peaked at $79.2M in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.